SAN DIEGO, Feb. 05, 2016 -- HempMeds® Mexico is the sales, marketing and distribution company for the first cannabidiol (CBD) hemp oil product granted special permission by the Mexican government for import. On Feb. 2, 2016, the country’s health administration, known as COFEPRIS, issued the first two import permits.
This historic decision now makes HempMeds® Mexico’s RSHO-XTM product available for use nationwide. The Company is now accepting orders and will begin shipping RSHO-XTM to Mexico on Feb. 8, 2016.
In the U.S., CBD hemp oil products are considered a “nutritional supplement” or “food product.” Hemp oil products are readily available online from HempMeds® and can be shipped to all 50 states, territories and districts.
However, much like the importation process in Brazil, the Mexican government currently considers RSHO-XTM a medication that requires a doctor’s prescription and import permit.
HempMeds® Mexico is offering three products:
- Real Scientific Hemp Oil-X™ Gold Label CBD Hemp Oil in the 10 gram oral applicator contains 2,500mg cannabidiol
- Real Scientific Hemp Oil-X™ Liquid Gold Label CBD Hemp Oil in 4 fl. oz. bottle contains 1,000mg cannabidiol
- Real Scientific Hemp Oil-X™ Liquid Gold Label CBD Hemp Oil in 8 fl. oz. bottle contains 5,000mg cannabidiol
HempMeds® Mexico will continue to be present as Mexico debates how to change its laws to conform with the landmark Mexican Supreme Court cannabis ruling in November 2015. It declared cannabis a fundamental human right for everyone in Mexico. That decision forced the government to overhaul its marijuana laws, and the nation is encouraged to get involved in the public debate. HempMeds® Mexico was there when Mexico’s legislature began its debate on marijuana reform Jan. 25, 2016.
HempMeds® Mexico will continue to be present at every public debate throughout the country through April 5. The Company will also continue to sponsor and hold informational events -- which launched last month, when HempMeds® Mexico helped host two historic educational forums in Mexico City and Monterrey -- along with premier partner, the “Por Grace Foundation.”
Click here to register with HempMeds® Mexico for instructions on how to begin the RSHO-XTM import process. To learn more about HempMeds® Mexico or to place an order contact the customer service department at:
US: 1-866-786-2440
MX: 001-866-786-2440
Additional information is listed on the HempMeds® Mexico website. For more information on RSHO-XTM, visit http://www.hempmeds.mx.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company, created to provide access to cannabinoid-based products including cannabidiol (CBD) hemp oil products as they become legal in the country of Mexico for the first time. Our Company is a sales, marketing and distribution company. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to our CBD hemp oil products. HempMeds® Mexico is the first company to legally ship RSHO-XTM CBD hemp oil into Mexico. For more information, please review the company’s website at: http://hempmeds.mx/.
About HempMeds®
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds® is the communication hub for the Medical Marijuana Inc. portfolio of companies.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact:
Public Relations contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
[email protected]
www.cmwmedia.com
Corporate contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Italy Fines Apple €98.6 Million Over App Store Dominance
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 



